What immunohistochemistry panel is recommended for the work‑up of osteosarcoma?

Immunohistochemistry Panel for Osteosarcoma

For osteosarcoma diagnosis, SATB2 is the most valuable immunohistochemical marker, demonstrating 90.4% sensitivity and 95.3% specificity, and should be the cornerstone of your IHC panel 1.

Core IHC Panel

The essential immunohistochemical workup for suspected osteosarcoma should include:

Primary Marker

• SATB2: This is your most reliable marker for osteogenic differentiation
  • Positive in 90.4% of all osteosarcomas 1
  • Particularly strong in osteoblastic (91.3%) and small cell osteosarcoma (87.5%) subtypes 1
  • Shows 100% positivity in chondroblastic and parosteal variants 1
  • Critical for distinguishing osteosarcoma from Ewing sarcoma (only 1.3% of Ewing sarcomas are SATB2-positive) 1

Supporting Markers for Differential Diagnosis

When osteosarcoma is in your differential, add these markers based on the clinical scenario:

• CD99: Essential to exclude Ewing sarcoma, which shows strong membranous positivity 2
• Molecular confirmation: For round cell variants, EWSR1 gene rearrangement testing via FISH or FET::ETS fusion detection is mandated to exclude Ewing sarcoma 2

Additional Markers for Specific Scenarios

• MDM2 (IHC or RNA-ISH): Specifically for low-grade osteosarcoma variants
  • Helps distinguish low-grade central osteosarcoma and parosteal osteosarcoma from benign mimics 3
  • RNA in situ hybridization shows 100% sensitivity and 96.2% specificity 3
  • Critical caveat: Avoid acid decalcification as it destroys RNA and compromises both FISH and RNA-ISH results 3

Important Diagnostic Pitfalls

SATB2 Limitations

• Cannot distinguish chondroblastic osteosarcoma from high-grade chondrosarcoma (46.6% of chondrosarcomas are SATB2-positive, particularly grade III lesions) 1
• In this scenario, identification of malignant osteoid matrix formation remains the diagnostic gold standard 1

Sample Handling Requirements

• Use nondecalcified samples whenever possible for molecular and IHC studies 2, 3
• Snap-freeze tissue for tumor banking and future molecular studies with patient consent 2
• Submit samples for microbiology, histology, and cytogenetic/molecular genetic studies including whole genome sequencing 2

Algorithmic Approach

1. First-line: SATB2 immunohistochemistry on nondecalcified tissue

   • If positive + malignant osteoid present → Osteosarcoma confirmed
   • If positive but no osteoid → Consider high-grade chondrosarcoma

2. If round cell morphology: Add CD99 and molecular testing

   • CD99 negative + SATB2 positive → Small cell osteosarcoma
   • CD99 positive + SATB2 negative + EWSR1 rearrangement → Ewing sarcoma

3. If low-grade lesion: Add MDM2 testing (RNA-ISH preferred over IHC for better sensitivity)

   • MDM2 amplified → Low-grade osteosarcoma variant
   • MDM2 negative → Consider benign bone lesions

Guideline-Mandated Requirements

All diagnostic specimens must be 2:

• Examined by an accredited bone tumor pathologist who is part of a bone sarcoma MDT
• Reported according to Royal College of Pathologists guidance and ICCR recommendations
• Discussed at a multidisciplinary bone sarcoma team meeting with surgeon, radiologist, pathologist, and oncologist present

The pathology request form must include anatomical site, patient age, and radiological differential diagnosis to guide appropriate marker selection 2.